FORMULATION AND EVALUATION OF DROTAVERINE HCL AND MEFENAMIC ACID DISPERSIBLE TABLETS
International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI) · 2026
DOI: 10.67540/ijppi.v1.i3.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI), 2026. Verfasst von TRIDEV KUMAR. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
The current investigation focused on the formulation and evaluation of dispersible tablets containing a combination of Drotaverine Hydrochloride (80 mg) and Mefenamic Acid (250 mg) to enhance patient compliance and offer a rapid therapeutic effect for the relief of pain caused by smooth muscle spasms. Dispersible tablets possess several advantages over conventional pharmaceutical formulations, particularly for pediatric and geriatric patients, due to their rapid disintegration and ease of administration. The formulation was developed using a prepared by direct compression method incorporating functional excipients with Kyron T 144 and sodium starch glycolate incorporated as superdisintegrants. ẞ-cyclodextrin employed to improve solubility, and Prosolv SMCC 90 used as a direct-compression diluent. PVP K30 was used as a binder, while sweeteners and flavoring agents were included to improve palatability. Pre-compression properties of the prepared granules were determined through angle of repose, bulk and tapped density, Carr's index, and Hausner ratio, which collectively confirmed adequate flow characteristics for subsequent compression. The resulting tablets were assessed for various post-compression characteristics, namely hardness, friability, weight variation, disintegration and wetting times, and drug content uniformity. The results demonstrated that all parameters were within acceptable pharmacopoeial limits. The selected optimized formulation showed prompt disintegration and acceptable mechanical integrity. In-vitro dissolution studies revealed enhanced drug release profiles, indicating improved availability of both active ingredients. In conclusion, the developed dispersible tablets of Drotaverine HCI and Mefenamic Acid showed promising characteristics in terms of rapid disintegration, improved dissolution, and patient-friendly making administration, them a suitable a suitable substitute for conventional oral formulations.
Zitieren
APA
KUMAR, T. (2026). FORMULATION AND EVALUATION OF DROTAVERINE HCL AND MEFENAMIC ACID DISPERSIBLE TABLETS. International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI). https://doi.org/10.67540/ijppi.v1.i3.027
Vancouver
KUMAR T. FORMULATION AND EVALUATION OF DROTAVERINE HCL AND MEFENAMIC ACID DISPERSIBLE TABLETS. International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI). 2026. doi:10.67540/ijppi.v1.i3.027
BibTeX
@article{KUMAR2026,
author = {KUMAR, TRIDEV},
title = {FORMULATION AND EVALUATION OF DROTAVERINE HCL AND MEFENAMIC ACID DISPERSIBLE TABLETS},
journal = {International Journal of Pharmacological and Pharmaceutical Innovations (IJPPI)},
year = {2026},
doi = {10.67540/ijppi.v1.i3.027}
}
EUVIMED